The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Pfizer reports positive data from late-stage BEACON CRC trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Results from the phase III BEACON CRC trial show significant improvements in overall survival and objective response rates for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet.

The trial evaluates the combination of Braftovi (encorafenib), Mektovi (binimetinib), and cetuximab (Braftovi Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy.

Pfizer sponsors the trial.

BRAFTOVI Triplet showed a median OS of 9.0 months, compared to 5.4 months for Control. An improved ORR of 26% was observed in BRAFTOVI Triplet compared to 2% for Control.

These data were presented Sept. 30 at ESMO.

The company expects to submit the results of the trial for marketing approval in the United States in Q4 2019.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.”

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
By Monica L. Baskin, Nadine J. Barrett, Kim F. Rhoads, Hayley S. Thompson, Kimlin Tam Ashing, Folakemi T. Odedina and Vanessa B. Sheppard

Art exhibit at University of Miami Sylvester bridges North and South America

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account